Ascension Sciences and Complex Biotech Discovery Ventures Announce Partnership to Launch Advanced Analytical Testing Services
VANCOUVER, October 1st, 2020 — Ascension Sciences Inc. (“ASI”), an independent laboratory focused on nanoparticle formulation development for cannabinoid products and therapeutics, is pleased to announce a collaboration with Complex Biotech Discovery Ventures (“CBDV”), a cannabis R&D firm focusing on chemical process development and extraction optimization to advance the cannabis industry.
This partnership will bring nanoparticle characterization, formulation, spectroscopy, calorimetry, diffraction, and other advanced analytical services to the emerging Canadian and global cannabis industries. Both companies will jointly provide research and development groups with advanced analytical testing solutions to streamline cannabis processing, chemical characterization and nanoparticle formulation development.
Dr. Markus Roggen, Founder of CBDV, commented, “With Ascension, we found an experienced partner to expand our research capabilities in a collaborative manner.”
“Ascension Sciences is proud to partner with CBDV. With cannabinoids being increasingly used as active ingredients in both recreational, health and therapeutic products, in-depth and accurate analyses of these constructs are imperative. We look forward to bringing our R&D expertise and proven knowledge in cannabinoid nanoparticles to these analytical services and future R&D projects with CBDV.” added Tomas Skrinskas, Founder & CEO of Ascension Sciences.
Complex Biotech Discovery Ventures (CBDV) is a licensed cannabis research laboratory focused on chemical process development, analytical testing, and extraction optimization. CBDV is dedicated to bringing a rigorous scientific foundation to the cannabis industry through their innovative research initiatives and consulting services. CBDV provides a wide range of scientific services and expertise involving all aspects of cannabis chemistry.
For more information, please visit https://cbdvl.com/
Employing nanoparticle formulation technology from the cutting edge of genetic medicine, Ascension Sciences Inc. (ASI) is developing cannabinoid nano delivery platforms and techniques for the pharma and nutraceutical industries. ASI’s R&D and formulation development services are an efficient option for research driven firms that require the advantages of nanoparticle delivery for their active ingredients.
For more information, please visit: https://ascensionsciences.com/